首页|培元抗癌汤联合多西他赛+顺铂方案治疗中晚期食管癌的疗效及对患者中医证候、免疫功能的影响

培元抗癌汤联合多西他赛+顺铂方案治疗中晚期食管癌的疗效及对患者中医证候、免疫功能的影响

扫码查看
目的 观察培元抗癌汤联合多西他赛+顺铂(DP)方案治疗中晚期食管癌的疗效及对患者中医证候、免疫功能的影响.方法 将104 例中晚期食管癌患者按照随机数字表法分为 2 组,对照组 52 例予DP方案化疗,治疗组 52例在对照组治疗基础上加培元抗癌汤.2 组3 周为1 个疗程,治疗3 个疗程.比较2 组疗效;比较2 组治疗前后中医证候评分、免疫功能指标、血清标记蛋白水平变化;观察2 组不良反应发生情况.结果 治疗组客观缓解率(ORR)71.15%(37/52),疾病控制率(DCR)84.62%(44/52);对照组ORR 51.92%(27/52),DCR 67.31%(35/52).治疗组疗效优于对照组(P<0.05).2 组治疗后口干咽燥、哽噎肿痛、神疲气短、面黄消瘦评分均较本组治疗前降低(P<0.05),且治疗组降低更明显(P<0.05).2 组治疗后CD3+、CD4+、CD4+/CD8+均较本组治疗前升高(P<0.05),CD8+较本组治疗前降低(P<0.05);治疗后治疗组CD3+、CD4+、CD4+/CD8+均高于对照组(P<0.05),CD8+低于对照组(P<0.05).2 组治疗后丝裂原活化蛋白激酶(MAPK)、半胱氨酸蛋白酶-3(Caspase-3)、B细胞活化因子受体(BAFF-R)水平均较本组治疗前降低(P<0.05),且治疗组降低更明显(P<0.05).2 组不良反应总发生率比较差异无统计学意义(P>0.05).结论 培元抗癌汤联合 DP方案治疗中晚期食管癌,能改善患者中医证候,提高免疫功能,抑制 MAPK、Caspase-3、BAFF-R表达水平,治疗安全性良好.
Effect of Peiyuan Kangai Decoction combined with docetaxel and cisplatin regimen on traditional Chinese medicine symptoms and immune function in advanced esophageal cancer
Objective To study the effect of Peiyuan Kangai Decoction combined with docetaxel and cisplatin(DP)regimen on traditional Chinese medicine(TCM)symptoms and immune function in advanced esophageal cancer.Methods A total of 104 patients with advanced esophageal cancer were randomly divided into control group(n=52)and treatment group(n=52).All patients were treated with DP chemotherapy scheme,those in the treatment group were additionally treated with Peiyuan Kangai Decoction.After 3 courses of treatment(3 weeks as a treatment course),the clinical efficacy,TCM symptom score,immune function index in the two groups were evaluated,the level of serum marker proteins and the occurrence of adverse reactions in the two groups were observed.Results The objective remission rate(ORR:71.15%[37/52]vs 51.92%[27/52])and disease control rate(DCR:84.62%[44/52]vs 67.31%[35/52])in the treatment group were significantly higher than those in the control group(P<0.05).After treatment,the TCM symptoms scores(including dry mouth and throat,choking swelling and pain,mental fatigue and breath shortness,yellow face and weight loss)in the both groups were significantly lower than before treatment(P<0.05),the decreases were more common in the treatment group relative to the control group(P<0.05).The levels of CD3+,CD4+and CD4+/CD8+in the both groups were significantly higher than before treatment(P<0.05),but CD8+level was significantly lower(P<0.05),the improvements were better in treatment group than in con-trol group(P<0.05).After treatment,the levels of mitogen-activated protein kinase(MAPK),caspase-3 and B cell activating factor receptor(BAFF-R)in the two groups were sig-nificantly decreased than those before treatment(P<0.05),and the decrease in the treatment group was more significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Peiyuan Kangai Decoction combined with DP regimen has good therapeutic effect in the treatment of advanced esophageal cancer.It can improve the TCM symptoms,improve the immune function,inhibit the expression level of MAPK,Caspase-3,BAFF-R and serum marker proteins.It has good therapeutic safety.

Esophageal cancerIntegrative medicine therapy

张鸿雁、孙兆、曹昌霞

展开 >

青海大学附属医院中西医结合科,青海 西宁 810000

食管肿瘤 中西医结合疗法

2020年青海省中藏医药科研创新项目青海大学附属医院中青年科研基金一般项目

J2020017AS-RF-2019-YB-19

2024

河北中医
河北省医学情报研究所,河北省中医药学会

河北中医

CSTPCD
影响因子:0.951
ISSN:1002-2619
年,卷(期):2024.46(7)
  • 13